Nadide

Overview

A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma	2024/09/11	NCT06590844	Phase 4	Active, not recruiting	Anhui Provincial Hospital
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT	2024/08/16	NCT06558253	Phase 1	Recruiting	Anhui Provincial Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Melatonin Forte	BioActive Nutritional, Inc.	43857-0020	ORAL	6 [hp_X] in 1 mL	5/14/2025
Bio Co Enzyme Phase	Deseret Biologicals, Inc.	43742-2259	ORAL	8 [hp_X] in 1 mL	4/8/2025
Energize	Parasitology Center Inc.	70321-0003	ORAL	10 [hp_X] in 1 mL	5/22/2025
Virexa	Oncora Pharma, LLC	85477-606	ORAL	5 mg in 1 1	9/5/2025
EnLyte Gummy plus	Jaymac Pharmaceutical	64661-222	ORAL	8.3 ug in 1 1	9/18/2025
Immuno-Boost	Parasitology Center, Inc.	70321-0002	ORAL	8 [hp_C] in 1 mL	5/22/2025
Reflux	Deseret Biologicals, Inc.	43742-1324	ORAL	6 [hp_C] in 1 mL	5/27/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
Genuine NAD+	372512	Life Biotech Pty Ltd	Medicine	A	8/9/2021
MELTMED Regenerate	413150	iX Biopharma Pty Ltd	Medicine	A	7/10/2023
A·V·I NAD+	378148	ALSL Pty Ltd	Medicine	A	11/17/2021
NAD+ AAA	495386	Renhe Biotech (Australia) Pty Ltd	Medicine	A	6/30/2025
BLACKSOILBIO NAD + Q10	495365	Biotech Co	Medicine	A	6/30/2025
Cellife NADH	409090	Cellife Health Products Pty Ltd	Medicine	A	5/17/2023
SL-NAD+ 100mg	469505	iX Biopharma Pty Ltd	Medicine	A	11/20/2024
Entity SL-NAD+ 100mg	459386	iX Biopharma Pty Ltd	Medicine	A	8/13/2024
SL-NAD+	371660	iX Biopharma Pty Ltd	Medicine	A	7/26/2021
SL NAD+	451685	iX Biopharma Pty Ltd	Medicine	A	6/11/2024

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
CUTISITUM	Biologische Heilmittel Heel Gmbh	02236489	Liquid - Oral	10 D	2/6/1998
UBICOENZYME	Biologische Heilmittel Heel Gmbh	02236503	Liquid - Oral	8 D	2/6/1998
DISCOMPEEL	Biologische Heilmittel Heel Gmbh	02236490	Liquid - Oral	10 D / D	2/6/1998
HEPAR COMPOSITUM	Biologische Heilmittel Heel Gmbh	02236496	Liquid - Oral	12 D	2/6/1998

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

FDA Reverses Position on NMN, Declares Supplement Ingredient Lawful After Industry Legal Challenge

2 months ago

The FDA has reversed its 2022 decision and now declares NMN (beta-nicotinamide mononucleotide) lawful for use in dietary supplements, citing evidence the ingredient was marketed in the U.S. as early as 2017.

Niagen Bioscience Secures Exclusive License for Nicotinamide Riboside as Parkinson's Disease Therapy

4 months ago

Niagen Bioscience has obtained worldwide exclusive commercial rights to develop nicotinamide riboside (Niagen) as a potential Parkinson's disease therapy through a licensing agreement with Haukeland University Hospital in Norway.

First Clinical Trial Shows Nicotinamide Riboside Improves Multiple Health Outcomes in Werner Syndrome Patients

5 months ago

Japanese researchers conducted the world's first rigorous clinical trial of nicotinamide riboside (NR) in Werner syndrome patients, showing significant improvements in cardiovascular health, skin ulcers, and kidney function.

Aging Impairs CAR-T Cell Therapy Effectiveness Through Metabolic Decline, Swiss Study Reveals

6 months ago

New research from Swiss institutions demonstrates that age-related immune decline significantly reduces the effectiveness of CAR-T cell cancer therapy by impairing mitochondrial function and metabolism.

Mitochondrial NAD+ Reservoir Vital for Cellular Health and Aging, Study Finds

a year ago

Researchers have discovered that mitochondria act as a crucial reservoir for NAD+, a molecule essential for cellular energy and function, maintaining cellular health.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access